NCT03339882View on ClinicalTrials.gov

Remifemin Preventing the Climacteric Symptoms in Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

85

Participants

Timeline

Start Date

January 4, 2017

Primary Completion Date

November 27, 2017

Study Completion Date

January 30, 2018

Conditions
Effect of DrugsSafety Issues
Interventions
DRUG

Remifemin

Remifemin 0.2g po bid\*12 weeks at the beginning of the LHRH-a treatment

Trial Locations (1)

310000

Zhejiang Cancer Hospital, Hangzhou

All Listed Sponsors
lead

Zhejiang Cancer Hospital

OTHER

NCT03339882 - Remifemin Preventing the Climacteric Symptoms in Breast Cancer | Biotech Hunter | Biotech Hunter